One hint that CTIX maybe on to something huge is that Kevetrin may actually require the modification of current definitions to account for its unique MOA. I have to agree with those who abdicate taking a starter position and adding as progress unfolds. Once one owns a few share they are more likely to do real DD and realize two is not the correct number for potential blockbuster drugs at Cellceutix.
News 
Market Data 
Discover 
AI
